FDA Approves Genentech’s Rozlytrek (entrectinib) for ROS1 Non-Small Cell Lung Cancer (NSCLC) and NTRK-Driven Tumors

2019-08-16T15:54:19+00:00August 16th, 2019|Hot Topics, News|

On August 15, 2019 the U.S. Food and Drug Administration approved Rozlytrek (entrectinib) for the treatment of patients with ROS1-positive, metastatic non-small cell lung cancer. It was also simultaneously approved for the treatment of patients with any solid tumor that is NTRK fusion-positive, following progression on other therapies. This approval offers a new targeted therapy option for patients with both of these rare mutations and is only the third time that the FDA has approved a targeted therapy for any [...]

Crisis and Relief: Reflections on World Lung Cancer Day

2019-08-01T17:23:46+00:00August 1st, 2019|Hot Topics|

World Lung Cancer Day is a time to remember that this disease remains a crisis around the globe. But is also a day to count the many ways that we’ve helped advance efforts on general awareness, early detection, research funding, innovative research, and support for patients and caregivers. Providing credible information about lung cancer and treatment options. Accessing our website are almost 30,000 individuals per month, with approximately 25% from outside the US. Visit the highest trafficked pages: What is Lung [...]

GO2 Foundation Presents 2019 Bonnie J. Addario Lectureship Award at ILCC

2019-07-30T20:33:21+00:00July 26th, 2019|Hot Topics, News|

GO2 Foundation for Lung Cancer is pleased to announce that it presented Solange Peters, MD, PhD, with the 2019 Bonnie J. Addario Lectureship Award for her emphasis on groundbreaking biomarker research, improving access to care for lung cancer patients worldwide, and supporting the advancement of women in oncology. GO2 Foundation honored Prof. Peters with the award at the International Lung Cancer Conference (ILCC) held July 25-27 in Huntington Beach, California. Read more.

An Update on the Burn Pits Accountability Act of 2019

2019-07-17T14:08:59+00:00July 17th, 2019|Hot Topics, News|

Click here to read our statement in support of the legislation. GO2 Foundation for Lung Cancer is pleased to report the recent advancement of the Burn Pits Accountability Act. We strongly support this legislation as a first step to ensure that all those affected by burn pit toxins are accounted for, in order to call for further research focused on these veterans. Since the Persian Gulf War, a common waste disposal practice at military sites outside the United States was [...]

New Treatment Approved for Metastatic Small Cell Lung Cancer

2019-06-18T21:13:13+00:00June 18th, 2019|Hot Topics, News|

On June 17, 2019, the U.S. Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA) for patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. Though pembrolizumab is an established treatment option for non-small cell lung cancer, this is the first approval of pembrolizumab for small cell lung cancer. This approval was based on two clinical trials, KEYNOTE-158 and KEYNOTE-028, which measured tumor [...]

Early Screening Equals Early Diagnosis

2019-06-18T16:14:25+00:00June 18th, 2019|Hot Topics, News|

GO2 Foundation for Lung Cancer’s recently published scientific paper found that lung cancer screening programs can successfully detect lung cancer early with the majority of lung cancers diagnosed at stage 1 or limited stage. Importantly, outcomes at academic and nonacademic sites were compared and the data confirmed that responsible screening can take place in a community setting. Figure B: Percentage of each stage and type of lung cancer diagnosed at nonacademic centers compared with academic centers. Published in [...]

Women’s Health Week: Our Fight Against Lung Cancer

2019-05-16T18:55:28+00:00May 16th, 2019|Hot Topics|

Lung cancer in women is a critical women’s health issue in the United States. An average of 181 women die each day of lung cancer—one every 8 minutes. In fact, two-thirds of the never-smoked lung cancer population is female. Why does the number of young women with lung cancer who have never smoked continue to rise? There is no clear answer, but we’re working to make sure research into this issue remains a priority. Last year, The NELSON Trial revealed women [...]

Join Our $20 Million By 2020 Campaign to Restore Full Funding for Lung Cancer Research!

2019-05-10T13:51:07+00:00May 9th, 2019|Hot Topics|

TAKE ACTION! Through consistent advocacy efforts, GO2­ Foundation (formerly Lung Cancer Alliance) established the Lung Cancer Research Program (LCRP) within the Congressionally Directed Medical Research Programs, administered by the Department of Defense with federal appropriations of $20 million in Fiscal Year (FY) 2009. LCRP has been underfunded the past 10 years, below its original $20 million dollars level. Congress must restore the funding level back to $20 million this year. Since FY09 and through FY18, the program has been funded [...]

Research Wins Big

2019-05-17T16:57:20+00:00May 7th, 2019|Hot Topics, News|

The GO2 Foundation for Lung Cancer is honored to announce that on May 2 two of our programs received Your Cancer’s Cancer Community (C2) Awards. These awards celebrate “the unsung heroes of cancer care”—individuals and organizations that advance cancer care and work to improve the lives of those living with the disease. The Centers of Excellence (COE) program received Your Cancer’s C2 Catalyst for Care Award. This category recognized nominees making the experience of cancer care easier for patients. We [...]